CTX120
- Generic Name
- CTX120
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
- Associated Conditions
- -
- Associated Therapies
- -
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 26
- Registration Number
- NCT04244656
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath